Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, and Cutaneous lymphoproliferative disorders research.
Left ventricular myocardial work combined with stress echocardiography assessment of cardiac function in patients with Fabry disease
527 | HIGH‐THROUGHPUT T CELL RECEPTOR SEQUENCING TO DETECT MEASURABLE RESIDUAL DISEASE IN SYSTEMIC T CELL LYMPHOMA TREATED WITH BRENTUXIMAB VEDOTIN: A PROSPECTIVE TRIAL
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study
Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes
Hodgkin Lymphoma, Version 2.2015
Prevalence and Clinical Implications of Epstein–Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines